−8.33USD
−606.64 MUSD
434.25 MUSD
77.02 M
About Ultragenyx Pharmaceutical Inc.
Sector
CEO
Emil D. Kakkis
Headquarters
Novato
Website
Employees (FY)
1.28 K
Founded
2010
ISIN
US90400D1081
FIGI
BBG001RWPDW6
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
$RARE Bat pattern @ PRZ zone trigger, TOP WATCH 💰$RARE will be top watch for tomorrow, watching this close in pre market, a pullback to 80$ would be lovely at 886 trigger although id take it on break over Fridays high w a tight stop, below low(fridays), take profits are labeled with tags in blue. Objective, get long get stop to break even asap ad
RARE 🌦Pattern recognized: Regular flat Elliot Correction Wave.
Thesis: Bullish sentiment.
Conclusion: waiting for fractal on the 5 min
My strategy: MEWT (MODIFIED ELLIOT WAVE THEORY).
***This does not constitute financial advice.***
$RAREEntry price : 139.28
Fundamentals :
- Sector: Medical - Biotech
- EPS % Chg (Last Qtr): 42%
- EPS % Chg (Previous Qtr): 124%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 216%
- Sales % Chg (Previous Qtr): 155%
- 3-Year Sales Growth Rate: 447%
- A
RARE OpportunityThe weekly shows this coming down to test the recent breakout from a multi-year base. Not a bad setup on the daily too.
RARE 1D Long +18% TargetNASDAQ:RARE stock analysis at 1D time frame, EMA20 and MACD(8,21,5) crossed up .
RSI (14) and RSI (7) > 50 , Relative Volume (over 3 month) > 3.0 all that yield to strong "Buy".
The target price will be at least +18%,
This is not a recommendation to "buy" or "sell", everyone should do according
textbook fakeout breakout here!this is what i call a fakeout break, broke 140 and tricked investors into thinking a new rally was coming, but sold aff right back under previous highs, bearish in short term bullish long term. ideal entry 110 sl 105 pt 140! goodluck :)
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of RARE is 43.38 USD — it has decreased by 1.65% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ultragenyx Pharmaceutical Inc. stocks are traded under the ticker RARE.
Ultragenyx Pharmaceutical Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
RARE stock is 3.42% volatile and has beta coefficient of 1.26. Check out the list of the most volatile stocks — is Ultragenyx Pharmaceutical Inc. there?
One year price forecast for Ultragenyx Pharmaceutical Inc. has a max estimate of 140.00 USD and a min estimate of 48.00 USD.
RARE earnings for the last quarter are −2.23 USD whereas the estimation was −2.08 USD which accounts for −7.35% surprise. Estimated earnings for the next quarter are −1.71 USD. See more details about Ultragenyx Pharmaceutical Inc. earnings.
Ultragenyx Pharmaceutical Inc. revenue for the last quarter amounts to 98.05 M USD despite the estimated figure of 109.60 M USD. In the next quarter revenue is expected to reach 119.38 M USD.
Yes, you can track Ultragenyx Pharmaceutical Inc. financials in yearly and quarterly reports right on TradingView.
RARE stock has fallen by 16.58% compared to the previous week, the month change is a 5.92% fall, over the last year Ultragenyx Pharmaceutical Inc. has showed a 6.64% increase.
RARE net income for the last quarter is −123.19 M USD, while the quarter before that showed −159.65 M USD of net income which accounts for 22.84% change. Track more Ultragenyx Pharmaceutical Inc. financial stats to get the full picture.
Today Ultragenyx Pharmaceutical Inc. has the market capitalization of 3.63 B, it has increased by 7.81% over the last week.
No, RARE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RARE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ultragenyx Pharmaceutical Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 1.28 K employees. See our rating of the largest employees — is Ultragenyx Pharmaceutical Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ultragenyx Pharmaceutical Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ultragenyx Pharmaceutical Inc. stock shows the sell signal. See more of Ultragenyx Pharmaceutical Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Ultragenyx Pharmaceutical Inc. future price: according to them, RARE price has a max estimate of 140.00 USD and a min estimate of 48.00 USD. Read a more detailed Ultragenyx Pharmaceutical Inc. forecast: see what analysts think of Ultragenyx Pharmaceutical Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ultragenyx Pharmaceutical Inc. EBITDA is −542.50 M USD, and current EBITDA margin is −125.09%. See more stats in Ultragenyx Pharmaceutical Inc. financial statements.